UroGen Pharma (NASDAQ:URGN) Earns Buy Rating from Analysts at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH initiated coverage on shares of UroGen Pharma (NASDAQ:URGN) in a report published on Wednesday, MarketBeat reports. The brokerage issued a buy rating and a $31.00 target price on the stock.

Separately, D. Boral Capital reissued a “buy” rating and issued a $25.00 target price on shares of UroGen Pharma in a research report on Tuesday. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, UroGen Pharma presently has a consensus rating of “Buy” and an average price target of $39.20.

UroGen Pharma Price Performance

URGN opened at $10.08 on Wednesday. The company has a 50-day moving average of $10.73 and a 200-day moving average of $12.20. The company has a market capitalization of $236.38 million, a P/E ratio of -3.20 and a beta of 1.08. UroGen Pharma has a 1-year low of $9.78 and a 1-year high of $20.70. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00.

Insider Transactions at UroGen Pharma

In other news, insider Mark Schoenberg sold 4,551 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the completion of the sale, the insider now directly owns 145,666 shares of the company’s stock, valued at approximately $1,622,719.24. This represents a 3.03 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Jason Drew Smith sold 7,379 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $82,202.06. Following the sale, the general counsel now directly owns 26,468 shares of the company’s stock, valued at approximately $294,853.52. This represents a 21.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.10% of the company’s stock.

Institutional Trading of UroGen Pharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Toronto Dominion Bank acquired a new stake in UroGen Pharma during the fourth quarter valued at approximately $18,628,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in UroGen Pharma by 2.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,377,156 shares of the company’s stock valued at $14,667,000 after purchasing an additional 36,084 shares during the last quarter. Vestal Point Capital LP lifted its stake in UroGen Pharma by 307.5% during the fourth quarter. Vestal Point Capital LP now owns 1,630,000 shares of the company’s stock valued at $17,360,000 after purchasing an additional 1,230,000 shares during the last quarter. Stonepine Capital Management LLC lifted its stake in UroGen Pharma by 15.7% during the fourth quarter. Stonepine Capital Management LLC now owns 324,324 shares of the company’s stock valued at $3,454,000 after purchasing an additional 43,979 shares during the last quarter. Finally, RTW Investments LP lifted its stake in UroGen Pharma by 1.3% during the fourth quarter. RTW Investments LP now owns 3,834,794 shares of the company’s stock valued at $40,841,000 after purchasing an additional 47,447 shares during the last quarter. 91.29% of the stock is owned by institutional investors and hedge funds.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.